peanut consumption

Peanut consumption, specifically the early introduction of infant-safe peanut-containing foods, is a dietary intervention used for the primary prevention of peanut allergy in high-risk infants. This approach was validated by the landmark Learning Early About Peanut Allergy (LEAP) trial, sponsored by the National Institute of Allergy and Infectious Diseases (NIAID). The intervention involves introducing peanut products (such as peanut butter or peanut puffs) to infants between 4 and 11 months of age who have severe eczema, egg allergy, or both. The biological mechanism involves the induction of oral immune tolerance, where early exposure to peanut allergens via the gastrointestinal tract promotes a protective immune response rather than sensitization. The LEAP study demonstrated an 81% reduction in peanut allergy development by age 5, leading to the 2017 NIAID Addendum Guidelines for the Prevention of Peanut Allergy in the United States.

Other names

early peanut introductionearly introduction of peanutLEAP trial interventionpeanut consumption group